ANANDA DEVELOPMENTS PLC

("Ananda" or the "Company")

An introduction to Cannabidiol (CBD) as a Pharmaceutical Medicine: Ananda releases whitepaper on CBD Therapeutic Potential

Ananda Developments plc (AQSE: ANA), a life sciences company focused on the research and development of CBD-based therapies for a range of complex inflammatory pain conditions, has today released a whitepaper entitled 'An introduction to Cannabidiol (CBD) as a Pharmaceutical Medicine'.

The report provides a comprehensive overview of CBD's potential therapeutic reach. Despite a growing body of anecdotal evidence and preclinical research, there remains a critical gap in robust clinical data to fully understand CBD's efficacy and safety for various medical conditions.

The whitepaper examines the historical use of cannabis as a medicine, providing a foundation for understanding the compound's potential. It goes on to further consider the complex biological mechanisms underlying CBD's effects, including, but not limited to, its interactions with the endocannabinoid system and other key physiological pathways.

The report also presents a detailed overview of the current state of knowledge regarding CBD's potential benefits in various disease areas, such as chronic pain, autoimmune disorders, and neurodegenerative conditions. By highlighting the gaps in current research, the report emphasises the need for further clinical investigation to unlock CBD's full therapeutic potential.

Key takeaways from the report include:

·    CBD interacts with a wide range of targets in the body, potentially impacting numerous conditions.

·    CBD exhibits various therapeutic properties, including anti-inflammatory, analgesic, anticonvulsant, and anxiolytic effects.

·    Existing evidence supports the potential benefits of CBD in treating a wide range of conditions, including chronic pain, various autoimmune diseases, and certain cancers.

·    More clinical trials are needed to confirm CBD's efficacy for various conditions and determine optimal formulations, dosages, and administration methods.

This resource is designed as a guide for healthcare professionals, researchers, investors and organisations wanting to understand more about the potential of the CBD molecule, the work that is being done and still needs to be done to better understand its efficacy.

Melissa Sturgess, Ananda CEO commented: "Ananda Developments is at the forefront of exploring the therapeutic potential of CBD-based medicines. This report highlights the vast potential of this fascinating molecule and underscores the need for further clinical research to bring this potential to fruition and offer new treatment options for patients with a variety of conditions."

Download the report here: https://investors.anandadevelopments.com/activity-updates/an-introduction-to-cbd

To stay up to date with the latest developments at Ananda, we encourage you to follow our social media channels which are:  

·      Register at our Investor Hub: https://investors.anandadevelopments.com/s/a66906

·      Instagram: https://instagram.com/anandadevelopments?igshid=YmMyMTA2M2Y=   

·      LinkedIn: https://www.linkedin.com/company/anadevelopments/   

·      Twitter: https://twitter.com/AnandaPlc

·      Investor Meet Company: https://www.investormeetcompany.com/ananda-developments-plc/register-investor

-Ends-

The Directors of the Company accept responsibility for the contents of this announcement.

For more information please contact:

About Ananda Developments

Ananda is an AQSE-listed company whose ambition is to be a leading provider of cannabinoid-based medicines for the treatment of complex, chronic inflammatory pain conditions.

For further information on the Company visit https://anandadevelopments.com/ or sign up at https://investors.anandadevelopments.com/s/a66906.

https://investors.anandadevelopments.com/link/lyaw2r